Skip to main content

 Scientific publications

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Year : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Checkpoints inhibitors in the (neo)adjuvant setting of solid tumors: lessons learnt and perspectives.

Authors : Kotecki N, Awada A
Year : 2019
Journal : Curr Opin Oncol

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Authors : Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A
Year : 2019
Journal : Curr Opin Oncol

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Authors : Kotecki N, Gombos A, Awada A
Year : 2019
Journal : Expert Rev Anticancer Ther
Volume : 19
Pages : 447-454

Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies.

Authors : El Ali Z, Rottey S, Barthelemy P, Kotecki N, VAN Paemel R, Devrient D, Awada A, Gil T, Pannier D, Ryckewaert T, Waisse W, Clavier JB, Penel N, Vermassen T
Year : 2019
Journal : Anticancer Res
Volume : 39
Pages : 2993-3002

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

Authors : Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, de Azambuja E
Year : 2018
Journal : Expert Rev Anticancer Ther
Volume : 18
Pages : 629-649

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.(article)

Authors : Kotecki N, Lefranc F, Devriendt D, Awada A
Year : 2018
Journal : Ther Adv Med Oncol
Volume : 10
Pages : 1758835918780312

Tackling the challenges of brain metastases in solid tumors.

Authors : Kotecki N, Awada A
Year : 2018
Journal : Curr Opin Oncol
Volume : 30
Pages : 330-331

How to emerge from the conservatism in clinical research methodology?

Authors : Kotecki N, Penel N, Awada A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(5)
Pages : 400-404

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Authors : Awada A, Penel N, Kotecki N
Year : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Authors : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Year : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Metabolic disorders associated with the use of targeted cancer therapies.

Authors : Kotecki N, Penel N, Awada A
Year : 2015
Journal : Curr Opin Oncol
Volume : 27(3)
Pages : 258-66